Blepharitis Market Report 2026

The blepharitis market size has grown rapidly in recent years. It will grow from $0.97 billion in 2025 to $1.09 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to poor eyelid hygiene, bacterial infections, ophthalmology clinic visits, aging population, chronic eye irritation.

The blepharitis market size is expected to see rapid growth in the next few years. It will grow to $1.73 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to screen time increase, digital eye strain, preventive eye care awareness, chronic condition management, outpatient ophthalmology growth. Major trends in the forecast period include increased awareness of chronic eye conditions, growth of lid hygiene and eye cleanser products, rising diagnosis of meibomian gland dysfunction, expansion of long-term symptom management, focus on non-invasive treatment options.

The increasing awareness regarding eye care is expected to drive the growth of the blepharitis market going forward. Eye care encompasses services, treatments, and practices aimed at maintaining and improving eye health and vision. Growing awareness is critical, as good vision supports independence, education, productivity, and overall well-being, while uncorrected vision problems can impair daily activities, academic performance, and work efficiency. Blepharitis contributes to effective eye care by promoting early symptom recognition, encouraging proper eyelid hygiene, and helping prevent complications such as dry eye and styes through timely treatment. For instance, in October 2024, according to the Association of Optometrists (AOP), a UK-based association, the number of people living with sight loss in the UK is projected to reach 2.8 million by 2035, representing a 27% increase compared to 2022. Therefore, increasing awareness regarding eye care is driving the growth of the blepharitis market.

Major companies in the blepharitis market are focusing on developing novel therapies, such as targeted anti-parasitic agents and advanced ophthalmic formulations, to gain a competitive edge. Innovative ophthalmic formulations are designed to improve the efficacy, safety, and patient experience of treatments for eye conditions. For instance, in July 2023, Tarsus Pharmaceuticals Inc., a US-based biopharmaceutical company, received FDA approval for XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. XDEMVY, formerly known as TP-03, is the first and only FDA-approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis. Its approval was based on two pivotal trials (Saturn-1 and Saturn-2) involving 833 patients, showing significant symptom improvement and higher rates of complete collarette cure compared to placebo. The recommended dosage is one drop in each eye twice daily for six weeks, and it is generally well tolerated, with mild stinging or burning being the most common side effect.

In July 2023, LianBio, a US-based biotechnology company, partnered with Tarsus Pharmaceuticals to expand access to XDEMVY for the treatment of Demodex blepharitis and meibomian gland disease in regions with significant unmet medical needs. This collaboration leverages strong clinical data and addresses a large patient population. Tarsus Pharmaceuticals Inc. specializes in developing novel therapies in the eye care sector.

Major companies operating in the blepharitis market are OcuSept Ltd., Alcon Inc., Théa Pharmaceuticals Ltd., Bausch Health Companies Inc., Tarsus Pharmaceuticals Inc., URSAPHARM Arzneimittel GmbH, Scope Ophthalmic Ltd., Santen Pharmaceutical Co. Ltd., NovaBay Pharmaceuticals Inc., Harrow Inc., MiBo Medical Group, Nicox SA, Visufarma S.p.A., OCuSOFT Inc., Lumenis Ltd., Bruder Healthcare Company, I-MED Pharma Inc., KALA Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Oyster Point Pharma Inc., Dompé Farmaceutici S.p.A., Laboratoires Théa S.A., Ophtecs Corporation, Sentiss Pharma Pvt. Ltd., Ajanta Pharma Ltd.

North America was the largest region in the blepharitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blepharitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blepharitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the blepharitis market by increasing the cost of importing ophthalmic antibiotics, eye cleansers, and diagnostic equipment used in disease management. Hospital-based and specialty center treatments are most impacted, particularly in North America and Europe where specialized eye care products are often imported. On the positive side, tariffs are encouraging domestic production of ophthalmic drugs and hygiene products, strengthening local supply chains.

The blepharitis market research report is one of a series of new reports that provides blepharitis market statistics, including blepharitis industry global market size, regional shares, competitors with a blepharitis market share, detailed blepharitis market segments, market trends and opportunities, and any further data you may need to thrive in the blepharitis industry. This blepharitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blepharitis is a common eye condition characterized by inflammation of the eyelids, usually at the base of the eyelashes. It can lead to redness, itching, crusting, and a gritty or burning sensation in the eyes. The condition is often chronic and may result from bacterial infections, skin disorders such as dandruff, or blocked oil glands.

The main types of blepharitis include anterior blepharitis, posterior blepharitis, and mixed blepharitis. Anterior blepharitis affects the front edge of the eyelid, where the eyelashes are attached. Treatments include eye cleansers, artificial tears, and antibiotic therapy. Diagnosis methods, such as physical examination and comprehensive eye exams, are applied in settings including hospitals and specialty eye care centers.

The blepharitis market consists of revenues earned by entities by providing services such as antibiotic therapy, topical corticosteroids, topical and oral antibiotics, ointments, and eye cleansers. The market value includes the value of related goods sold by the service provider or included within the service offering. The blepharitis market also includes sales of steroid eye drops, ointments, eyelid cleansers, lid scrubs, and warm compress masks. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.